Agios Appoints Catherine Owen to Board of Directors - Seite 2

Previously, Ms. Owen was a senior executive at Johnson & Johnson. During her more than 25 years there, she held leadership roles in pharmaceuticals, medical devices and corporate innovation in the U.K., the U.S., Europe and global organizations. In her last role, she was president, immunology, U.S. at Janssen Pharmaceuticals, leading brands such as Stelara, Remicade, Simponi and Tremfya, serving patients within the areas of dermatology, gastroenterology and rheumatology. Ms. Owen has an honors degree in pharmacy from the University of Manchester, U.K., is a member of the Royal Pharmaceutical Society of Great Britain and obtained a post-graduate diploma in marketing from the University of London. She has received numerous awards including the Medical Marketing and Media (MM+M) Hall of Femme Award in 2020 and the Healthcare Businesswomen’s Association Luminary Award in 2018.

“Agios is at an exciting and critical juncture, with two potential near-term launches in thalassemia and sickle cell disease, and I am thrilled to have the opportunity to contribute to maximizing the impact of Agios’ innovations for patients around the world,” said Ms. Owen. “I look forward to partnering with the rest of the board and the leadership team as the company enters this catalyst-rich period and beyond.”

“It’s been an honor to serve on the Agios board for nearly a dozen years. Over this time, the company brought three transformative medicines to patients with hematologic malignancies and rare diseases, and I couldn’t be more proud of the Agios team for these remarkable accomplishments,” said Dr. Maraganore. “I am excited about the future for Agios, and I look forward to continued progress in the years to come.”

About Agios
Agios is a biopharmaceutical company that is fueled by connections. The Agios team cultivates strong bonds with patient communities, healthcare professionals, partners and colleagues to discover, develop and deliver therapies for rare diseases. In the U.S., Agios markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for this rare, lifelong, debilitating hemolytic anemia. Building on the company's leadership in the field of cellular metabolism, Agios is advancing a robust clinical pipeline of investigational medicines with programs in alpha- and beta-thalassemia, sickle cell disease, pediatric PK deficiency and MDS-associated anemia. In addition to its clinical pipeline, Agios has a PAH stabilizer in preclinical development as a potential treatment for phenylketonuria (PKU) and deep scientific expertise in classical hematology. For more information, please visit the company’s website at www.agios.com.